Pan-sarbecovirus Vaccine TPP, United States
Mucosal COVID-19 Booster Vaccines TPP, United States
Pan-Sarbecovirus Vaccine TPP, International
Mucosal COVID-19 Booster Vaccines TPP, International
Lead coordinator: Aman Patel (aman.patel@pandemicdefense.tech)
Protocol
To develop these TPPs, we followed a protocol inspired by those used in UNICEF/NEST360’s newborn care TPPs.
Initial draft
Drawing on the existing WHO TPP for COVID-19 vaccines, we prepared initial drafts of each TPP.
Written comment phase
We sent the initial drafts of both TPPs to ~180 academic experts, regulators, and industry leaders whose activities or experience were relevant to mucosal COVID-19 boosters or pan-sarbecovirus vaccines. Reviewers were able to provide freeform written comments on each target criterion and propose new target criteria.
We revised both TPP drafts to incorporate received comments.
Consensus meeting
Around 1 month after sending out the drafts for comment, we hosted a virtual consensus meeting. Everyone who was invited to provide written comments on the draft TPPs was also invited to this meeting.
The consensus meeting was structured around freeform discussions of potential revisions to the three targets with least agreement in the written comment phase. If reviewers did not provide written comments on a target criterion, we assumed their agreement with that target.
After discussion of potential revisions to each target, we held a vote to ensure that the suggested changes had consensus from meeting participants. All discussion was under Chatham House rule to facilitate frank conversation.
Final review
We incorporated suggested changes from the consensus meeting into the TPPs, and completed final review and editing of the documents. We invited all participants in the TPP development process to be listed as contributors.